Across TCGA pan-cancer cohorts, RPL5P19 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated RPL5P19 data layer.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPL5P19 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL5P19 expression acts as an unfavorable survival marker.
HNSC, ACC, and STAD are the cancer types where RPL5P19 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.